EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Virus-like Particle Vaccines and Platforms for Vaccine Development

Milad Kheirvari iD, Hong Liu, Ebenezer Tumban

Viruses · 02.05.2023 · 15 (5) · 1109

DOI: 10.3390/v15051109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 02.05.2023. Verfasst von Milad Kheirvari und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA. Hauptthemen laut MEDLINE: Vaccines, Virus-Like Particle, Viruses. Die Arbeit wurde bisher 157-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, School of Veterinary Medicine at Texas Tech University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approved; they are very efficacious and offer long-lasting immune responses. Besides these, VLPs from other viral infectious agents (that infect humans, animals, plants, and bacteria) are under development. These VLPs, especially those from human and animal viruses, serve as stand-alone vaccines to protect against viruses from which the VLPs were derived. Additionally, VLPs, including those derived from plant and bacterial viruses, serve as platforms upon which to display foreign peptide antigens from other infectious agents or metabolic diseases such as cancer, i.e., they can be used to develop chimeric VLPs. The goal of chimeric VLPs is to enhance the immunogenicity of foreign peptides displayed on VLPs and not necessarily the platforms. This review provides a summary of VLP vaccines for human and veterinary use that have been approved and those that are under development. Furthermore, this review summarizes chimeric VLP vaccines that have been developed and tested in pre-clinical studies. Finally, the review concludes with a snapshot of the advantages of VLP-based vaccines such as hybrid/mosaic VLPs over conventional vaccine approaches such as live-attenuated and inactivated vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, Virus-Like ParticleVirusesAnimalsHumansHepatitis B virusVaccine Development

Stichwörter der Autor:innen

chimeric VLPsefficacyimmunogenicityvaccinesvirus-like particles

Substanzen

Vaccines, Virus-Like Particle

Autor:innen und Institutionen

  • School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA.

ORCID-Profile: Milad Kheirvari

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • School of Veterinary Medicine at Texas Tech University
  • US National Institutes of Health (National Institute of Allergy and Infectious Diseases)

Zitieren

APA

Kheirvari, M., Liu, H., & Tumban, E. (2023). Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses, 15(5), 1109. https://doi.org/10.3390/v15051109

Vancouver

Kheirvari M, Liu H, Tumban E. Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses. 2023;15(5):1109. doi:10.3390/v15051109

BibTeX
@article{Kheirvari2023,
  author = {Kheirvari, Milad and Liu, Hong and Tumban, Ebenezer},
  title = {Virus-like Particle Vaccines and Platforms for Vaccine Development},
  journal = {Viruses},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1109},
  doi = {10.3390/v15051109}
}
Kostenlos starten →